The Venture Codex

Participated · Series B · Aug 2025

Incyclix Bio is advancing INX-315, a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor, as its lead clinical compound. INX-315 is in a Phase 1/2 open-label, dose-escalation, combination and dose-expansion trial (NCT05735080) targeting advanced and metastatic breast and ovarian cancers, including CDK4/6 inhibitor resistant ER+/HER2- breast cancer and CCNE1-amplified solid tumors. The company positions itself as a scientific leader in understanding CDKs and their role in the cell cycle, and was founded by pioneers in CDK inhibitor discovery, research and development. Headquartered in Research Triangle Park, N.C., Incyclix is focusing resources on advancing INX-315 through clinical development with the recent Series B extension funding. No revenue or user metrics were disclosed in the announcement.